Jointly presented by the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing

Supported by educational grants from Bristol-Myers Squibb, Gilead Sciences, Inc., and Merck & Co., Inc.

dkb header

High Efficacy of Sofosbuvir/Velpatasvir plus GS-9857 for 12 Weeks in Treatment-experienced Genotype 1-6 HCV-Infected Patients, Including those Previously Treated with Direct-acting Antivirals

a podcast by Raymond T. Chung, MD and Eric Lawitz, MD dkb icon

You are using an outdated browser. Please upgrade your browser or activate Google Chrome Frame to improve your experience.